GSC2 Antibody

What is GSC2 and its biological significance?

GSC2 (GS homeobox 2), also known as GSH2, GSCL, or Homeobox protein goosecoid-2, is a homeodomain-containing transcription factor involved in developmental processes. It belongs to the paired-like class of homeobox proteins and functions as a DNA-binding transcriptional regulator. The protein has a molecular weight of approximately 32 kilodaltons and plays crucial roles in neuronal differentiation and developmental patterning . GSC2 is structurally characterized by its homeodomain, which facilitates DNA binding and subsequent regulation of target gene expression during embryonic development.

What types of GSC2 antibodies are available for research applications?

Several types of GSC2 antibodies are available for research purposes, including:

• Monoclonal antibodies (e.g., clone HL2135) - Offer high specificity and reproducibility for consistent results across experiments

• Polyclonal antibodies - Recognize multiple epitopes and potentially provide higher sensitivity

• Region-specific antibodies (e.g., C-terminal specific) - Target distinct domains of the GSC2 protein

These antibodies are available in various formats suitable for different experimental applications, including unconjugated forms for standard detection methods and conjugated variants for specialized techniques.

What are the primary research applications for GSC2 antibodies?

GSC2 antibodies are utilized across multiple experimental platforms:

Each application requires specific optimization for antibody concentration, incubation conditions, and detection methods to achieve reliable results.

How should I validate GSC2 antibody specificity before experimental use?

Validating antibody specificity is crucial to ensure experimental reliability:

• Positive and negative controls: Use tissues or cell lines known to express or lack GSC2 expression. Immortalized cell lines like 293, HepG2, and COLO205 have been documented for GSC2 expression validation .

• Western blot validation: Look for a single band at the expected molecular weight (approximately 21-32 kDa) depending on post-translational modifications .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to your sample. Signal disappearance confirms specificity.

• Genetic knockdown: Compare antibody staining in wild-type versus GSC2 knockdown/knockout samples. Reduced signal in knockdown samples confirms specificity.

• Cross-reactivity assessment: Test reactivity against closely related homeobox proteins to ensure selective GSC2 detection.

Many suppliers perform these validations, but independent verification in your experimental system is recommended for rigorous research.

What are the optimal conditions for GSC2 antibody use in Western blot analysis?

For optimal Western blot results with GSC2 antibodies:

• Sample preparation:

  • Extract proteins using RIPA or NP-40 based lysis buffers containing protease inhibitors

  • Determine protein concentration (BCA/Bradford assay)

  • Load 20-30 μg total protein per lane

• Gel electrophoresis:

  • 10-12% SDS-PAGE is appropriate for GSC2's molecular weight

  • Include molecular weight markers spanning 15-40 kDa range

• Transfer conditions:

  • Semi-dry or wet transfer at 100V for 60-90 minutes

  • Use PVDF membrane (0.45 μm pore size) for optimal protein retention

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Dilute primary antibody 1:500-1:2000 in blocking buffer

  • Incubate overnight at 4°C or 2 hours at room temperature for high target concentration

  • Use HRP-conjugated secondary antibodies at 1:5000-1:10000 dilution

• Detection:

  • Enhanced chemiluminescence (ECL) detection is suitable for GSC2 visualization

  • Exposure times may vary based on expression levels

Optimization for each specific antibody and sample type may be necessary to achieve clean, reproducible results.

What are the recommended protocols for cell-based GSC2 detection assays?

For cell-based detection of GSC2:

• Cell preparation:

  • Seed approximately 20,000 adherent cells per well in 96-well plates

  • For suspension cells, pre-coat wells with Poly-L-Lysine before seeding

  • Allow cells to adhere overnight or for at least 6 hours at 37°C, 5% CO₂

• Fixation and permeabilization:

  • Gently aspirate media and rinse with TBS

  • Fix with 4% paraformaldehyde (adherent cells) or 8% paraformaldehyde (suspension cells) for 20 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 in PBS for 10 minutes

• Antibody incubation:

  • Block with appropriate blocking buffer for 1 hour at room temperature

  • Incubate with primary anti-GSC2 antibody at 1:100 dilution overnight at 4°C

  • Apply secondary antibody (typically HRP-conjugated) for 1.5 hours at room temperature

• Signal development and quantification:

  • For colorimetric detection, add substrate and develop for 15-20 minutes

  • Add stop solution and read absorbance at 450 nm

  • For cell normalization, Crystal Violet staining can be performed after antibody detection

These protocols should be optimized for specific cell types and experimental conditions.

How can I resolve weak or absent GSC2 signal in immunodetection assays?

When encountering weak or absent GSC2 signals:

• Antibody concentration:

  • Increase primary antibody concentration (reduce dilution)

  • Extend primary antibody incubation time to overnight at 4°C

• Sample preparation:

  • Ensure protein extraction efficiency with appropriate lysis buffers

  • Include protease inhibitors to prevent GSC2 degradation

  • Verify total protein loading with housekeeping controls like GAPDH

• Antigen retrieval:

  • For fixed tissues or cells, optimize antigen retrieval methods (heat-induced or enzymatic)

  • Test different fixation protocols that might better preserve GSC2 epitopes

• Signal amplification:

  • Use biotin-streptavidin amplification systems

  • Consider tyramide signal amplification for immunohistochemistry/immunofluorescence

  • Utilize more sensitive detection reagents (e.g., SuperSignal West Femto)

• Expression verification:

  • Confirm GSC2 expression in your sample type using RT-PCR

  • Consider whether developmental timing or experimental conditions might affect expression levels

What are common sources of non-specific binding with GSC2 antibodies and how can they be mitigated?

Non-specific binding can compromise experimental interpretation. Common sources and solutions include:

• Inadequate blocking:

  • Extend blocking time to 2 hours or overnight

  • Test alternative blocking agents (BSA, normal serum, commercial blockers)

  • Include 0.1-0.3% Triton X-100 in blocking buffer for membrane permeabilization

• Secondary antibody cross-reactivity:

  • Use secondary antibodies specifically matched to host species of primary antibody

  • Pre-adsorb secondary antibodies against tissue from experimental species

  • Include negative controls omitting primary antibody

• Sample-specific interference:

  • Include additional washing steps (5-6 washes of 5 minutes each)

  • Add 0.05-0.1% Tween-20 to wash buffers

  • Pre-incubate antibodies with potential cross-reactive proteins

• Antibody quality issues:

  • Use affinity-purified antibodies where available

  • Test multiple antibody clones or lots

  • Store antibodies according to manufacturer recommendations to prevent degradation

• Signal-to-noise optimization:

  • Reduce substrate incubation time

  • Optimize exposure settings for imaging

  • Consider background quenching reagents

How can GSC2 antibodies be used to study developmental processes in neural tissues?

GSC2/GSH2 plays important roles in neural development, making antibody-based detection valuable for developmental neurobiology:

• Temporal expression analysis:

  • Use GSC2 antibodies on tissue sections at different developmental timepoints

  • Combine with markers of neural progenitors and differentiated neurons

  • Quantify expression changes during neural tube formation and brain regionalization

• Lineage tracing studies:

  • Combine GSC2 immunostaining with BrdU or EdU labeling to track proliferating cells

  • Use with cell-type specific markers to identify GSC2-expressing neural populations

  • Perform co-localization studies with other transcription factors involved in neural patterning

• GSC2 in neuronal differentiation:

  • Apply to stem cell differentiation models (embryonic stem cells or induced pluripotent stem cells)

  • Monitor GSC2 expression during transition from neural progenitors to specific neuronal subtypes

  • Correlate GSC2 levels with acquisition of neuronal morphology and function

• Functional perturbation studies:

  • Compare GSC2 expression between wild-type and genetically modified models

  • Assess downstream effects of GSC2 knockdown/overexpression on neural development

  • Investigate interaction with signaling pathways regulating neurogenesis

These applications require careful antibody validation specifically in neural tissues, as expression patterns may vary across developmental stages and anatomical regions.

How do I interpret contradictory results obtained with different GSC2 antibodies?

Contradictory results between different antibodies are a common research challenge. Systematic troubleshooting approach includes:

• Epitope mapping analysis:

  • Determine the target epitopes of each antibody (N-terminal, C-terminal, or internal domains)

  • Consider whether post-translational modifications might affect epitope accessibility

  • Assess whether alternative splicing could generate protein variants lacking specific epitopes

• Validation comparison:

  • Review validation data for each antibody (Western blot bands, immunostaining patterns)

  • Compare specificity confirmation methods used by manufacturers or in literature

  • Evaluate cross-reactivity profiles with related proteins

• Technical verification:

  • Test both antibodies under identical conditions on the same samples

  • Perform parallel experiments with positive and negative controls for each antibody

  • Consider whether differences in antibody format (monoclonal vs. polyclonal) explain discrepancies

• Correlation with non-antibody methods:

  • Validate findings using mRNA expression analysis (RT-PCR, RNA-seq)

  • Consider genetic approaches (fluorescent protein tagging, CRISPR/Cas9 epitope tagging)

  • Use mass spectrometry for protein identification if feasible

• Literature context:

  • Compare your findings with published results using the same antibodies

  • Assess whether contradictions reflect biological complexity rather than technical issues

  • Consider whether developmental timing or experimental conditions explain differences

When publishing, transparently report observed discrepancies and provide detailed methodological information for each antibody used.

What is known about GSC2's association with human diseases and potential clinical applications?

While GSC2 research primarily focuses on basic developmental biology, emerging evidence suggests potential disease associations:

• Neurodevelopmental disorders:

  • As a transcription factor involved in neural development, GSC2 alterations may contribute to neurodevelopmental conditions

  • Research is examining possible associations with intellectual disability and autism spectrum disorders

  • Antibody-based detection could help characterize GSC2 expression in patient-derived cells or tissues

• Cancer biology:

  • Aberrant expression of developmental transcription factors, including homeobox proteins, has been linked to oncogenesis

  • GSC2 expression screening in tumor samples might reveal diagnostic or prognostic biomarkers

  • Evaluating GSC2 in cancer stem cell populations could provide insights into tumor initiation

• Crohn's disease:

  • Some research suggests associations between antibodies and genetic variants in inflammatory bowel diseases

  • While most studies focus on anti-GP2 rather than GSC2, future research might explore potential connections

• Therapeutic targeting considerations:

  • Understanding GSC2 function could help identify downstream targets for therapeutic intervention

  • Antibodies against GSC2 might serve as research tools for validating potential drug targets

  • Transcription factor targeting remains challenging but represents an active area of drug discovery

Current evidence for clinical applications remains preliminary, highlighting the need for further research to establish definitive disease associations.

How can GSC2 antibodies be integrated with advanced imaging and single-cell techniques?

Integration of GSC2 detection with cutting-edge technologies enhances research capabilities:

• Super-resolution microscopy:

  • Apply GSC2 antibodies in STED, STORM, or PALM microscopy for nanoscale localization

  • Combine with chromatin or nuclear envelope markers to study nuclear organization

  • Visualize co-localization with transcriptional machinery components at unprecedented resolution

• Single-cell protein analysis:

  • Incorporate GSC2 antibodies in mass cytometry (CyTOF) panels for multi-parameter cellular analysis

  • Use in microfluidic antibody capture for single-cell protein profiling

  • Combine with single-cell transcriptomics to correlate protein and mRNA expression

• Spatial transcriptomics integration:

  • Perform GSC2 immunostaining in conjunction with spatial transcriptomics techniques

  • Correlate protein localization with target gene expression domains

  • Map GSC2 activity within tissue microenvironments

• Live cell imaging approaches:

  • Develop cell-permeable antibody derivatives or nanobodies for live GSC2 tracking

  • Combine with CRISPR-based labeling of GSC2 genomic targets to visualize protein-DNA interactions

  • Monitor dynamic changes in GSC2 localization during cellular processes

These integrative approaches require careful optimization of antibody performance under specific technical conditions, often necessitating specialized fixation, permeabilization, and detection protocols.